• Join
  • Login
  • Contact

Search abstracts

Translating Preclinical Safety Signals to the Clinic to Inform Compound Discovery and Early Development

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Presentation
  • By: METTETAL, Jay (AstraZeneca, Drug Safety and Metabolism, Waltham, United States)
  • Co-author(s): Jay Mettetal: Drug Safety and Metabolism, AstraZeneca, Waltham, United States
  • Abstract:

    Safety related findings remains a significant driver of compound attrition, particularly during late preclinical and early clinical development. A clearer picture of how early preclinical safety signals translate into man would allow a more accurate assessment potentially lowering attrition and resulting in safer drugs.

    Two common questions in


  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses